Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4772 Comments
1384 Likes
1
Cyrano
Returning User
2 hours ago
Impressed by the dedication shown here.
👍 100
Reply
2
Tmothy
Regular Reader
5 hours ago
I would watch a whole movie about this.
👍 59
Reply
3
Shamita
Regular Reader
1 day ago
I need to connect with others on this.
👍 72
Reply
4
Asiha
Influential Reader
1 day ago
Overall trading activity suggests moderate optimism, but short-term corrections remain possible.
👍 77
Reply
5
Ineva
Insight Reader
2 days ago
Too late… regret it now. 😭
👍 51
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.